EUCTR2008-001537-10-IT进行中（未招募）不适用
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER - TRIBE
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 个研究点开始时间: 2009年1月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven diagnosis of colorectal cancer
- •Not resectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease
- •At least one measurable lesion according to RECIST criteria
- •Age 18-75 years
- •ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years
- •Life expectancy of at least 12 weeks
- •Neutrophils ³1.5 x 109/L, Platelets ³100 x 109/L, Hgb >9 g/dl
- •Total bilirubin £1.5 time the upper-normal limits (UNL) of the Institutional normal values and ASAT (SGOT) and/or ALAT (SGPT) £2.5 x UNL, or £5 x UNL in case of liver metastases, alkaline phosphatase £2.5 x UNL, £5 x UNL in case of liver metastases.
- •Creatinine clearance >50 mL/min or serum creatinine £1.5 x UNL
- •Urine dipstick of proteinuria <2+. Patients discovered to have ³2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate £1 g of protein/24 hr.
- •Written informed consent.
- •Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating Center
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Radiotherapy to any site within 4 weeks before the study.
- •Untreated brain metastases or spinal cord compression or primary brain tumours.
- •History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke).
- •Serious, non-healing wound, ulcer, or bone fracture.
- •Evidence of bleeding diathesis or coagulopathy.
- •Uncontrolled hypertension.
- •Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication.
- •Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes.
- •Chronic, daily treatment with high-dose aspirin (>325 mg/day).
- •Treatment with any investigational drug within 30 days prior to enrolment.
- •Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications.
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
- •Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- •Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- •Symptomatic peripheral neuropathy ³ grade 1 according the NCI Common Toxicity Criteria.
研究者
相似试验
进行中（未招募）
1 期
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 StudyMetastatic colorectal cancerCTIS2023-506632-32-00Gruppo Oncologico Del Nord Ovest238
已完成
3 期
Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000001396West Japan Oncology Group400
进行中（未招募）
1 期
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-004394-40-ITFondazione GONO432
进行中（未招募）
1 期
folfoxiri plus bevacizumab plus atezolizumab or folfoxiri plus bevacizumab nel carcinoma del colonretto metastatico.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2017-000977-35-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST201
进行中（未招募）
不适用
A RANDOMIZED, PHASE 2 STUDY OF FOLFOX OR FOLFIRI WITH AG-013736OR BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTALCANCER AFTER FAILURE OF AN IRINOTECAN OR OXALIPLATINCONTAININGFIRST-LINE REGIMEN - NDEUCTR2007-006283-30-ITPFIZER176